Watson CEO Bisaro Ordered To Comply With FTC Subpoena
This article was originally published in The Pink Sheet Daily
Bisaro must testify about a settlement agreement to delay marketing generic Provigil, a federal judge says; decision follows a magistrate judge's recommendation.
You may also be interested in...
Teva’s March 30 authorized generic launch appears to give it a jump over other modafinil ANDA holders, who had settled patent litigation with Cephalon and were expected to enter the market in April. Several companies are expected to share 180-day marketing exclusivity rights for modafinil, although the fate of Ranbaxy’s ANDA under a recently negotiated FDA consent decree remains unclear.
A D.C. magistrate judge grants FTC's request to enforce a subpoena against Bisaro and finds the agency did not share Watson's confidential information with Apotex.
Watson CEO Paul Bisaro is fighting an FTC subpoena to testify in the commission's investigation of a reverse settlement agreement involving Cephalon's Provigil.